Difficulty: Medium
Average Score: 68%
Practice
Which of the following is a first-line treatment for systemic lupus erythematosus?
Correct answer
D
Rationale
In managing systemic lupus erythematosus (SLE), a multisystem autoimmune disease, the first-line treatment often includes hydroxychloroquine (Option D). Hydroxychloroquine is considered a cornerstone therapy for SLE as it helps in controlling disease activity, reducing flares, and protecting against organ damage. It is beneficial in managing skin and joint symptoms commonly seen in SLE patients. Additionally, hydroxychloroquine has been shown to improve overall outcomes and reduce mortality in SLE.
Corticosteroids (Option A) are commonly used in the treatment of SLE to quickly suppress inflammation during disease flares. However, they are typically used in conjunction with other medications for long-term management due to their potential for significant side effects when used alone or for extended periods.
Mycophenolate mofetil (Option B) and azathioprine (Option C) are immunosuppressive medications that are often used in SLE when patients do not respond adequately to first-line therapies or in cases of severe organ involvement. They are considered second-line treatments due to their stronger immunosuppressive effects and potential for more serious side effects compared to hydroxychloroquine.
In an educational context, understanding the rationale behind treatment choices in SLE is crucial for nurses working with pediatric patients with this condition. By knowing the appropriate first-line therapy like hydroxychloroquine, nurses can contribute to effective disease management, symptom control, and improved quality of life for pediatric patients with SLE. It is important for nurses to stay updated on current treatment guidelines and be able to explain the rationale behind different treatment options to patients and their families.
Corticosteroids (Option A) are commonly used in the treatment of SLE to quickly suppress inflammation during disease flares. However, they are typically used in conjunction with other medications for long-term management due to their potential for significant side effects when used alone or for extended periods.
Mycophenolate mofetil (Option B) and azathioprine (Option C) are immunosuppressive medications that are often used in SLE when patients do not respond adequately to first-line therapies or in cases of severe organ involvement. They are considered second-line treatments due to their stronger immunosuppressive effects and potential for more serious side effects compared to hydroxychloroquine.
In an educational context, understanding the rationale behind treatment choices in SLE is crucial for nurses working with pediatric patients with this condition. By knowing the appropriate first-line therapy like hydroxychloroquine, nurses can contribute to effective disease management, symptom control, and improved quality of life for pediatric patients with SLE. It is important for nurses to stay updated on current treatment guidelines and be able to explain the rationale behind different treatment options to patients and their families.